A Pharmaceutical composition in the form of a suspension comprising oxcarbazepine, and which, when it is agitated, a viscosity at the scale of 5 to 52 MPa. S.A Pharmaceutical composition in the form of a suspension comprising Oxcarbazepine and a mixture of Carboxymethyl Cellulose and microcrystalline Cellulose, on a scale of 1 to 1.25.95% (g / ml) of the total composition.A composition according to claim 2, wherein the proportion of Carboxymethylcellulose to microcrystalline Cellulose in the mix is 1: 5 to 1: 12.A composition according to claim 2 or 3, where the mixture is a Carboxymethyl Cellulose sodium salt.A composition according to any one of claims 1 to 4, which includes an Antioxidant.A composition according to claim 5, wherein the Antioxidant is Ascorbic acid.A composition according to claim 5 or 6, where the Antioxidant is present on a scale of 0 to 2 percent (g / ml) of the total composition.A composition according to any of the preceding Claims, that has a pH in the scale of 2 to 4.A composition according to any of the preceding Claims, comprising Oxcarbazepine in an amount of 1 to 20% (g / ml).A Pharmaceutical composition in the form of a suspension comprising Oxcarbazepine and less than 0.5 percent (g / ml) of hydroxyethylcellulose.A container with a filling volume of approximately 50 milliliters, 300 milliliters.A suspension comprising Oxcarbazepine according to any of the preceding Claims, and a dosing syringe adapted to conform to this container.A Pharmaceutical composition in the form of a thixotropic suspension oral comprising 6% (g / ml) of oxcarbazepine, and which, when it is agitated,A viscosity at the scale of 5 to 52 MPa. S.Denne oppfinnelsen tilveiebringer en farmasøytisk sammensetning på formen av en suspensjon som omfatter oxcarbazepin.
